Current situation and future of stem cells in cardiovascular medicine

Nasser, Moussa Ide; Qi, Xiao Wei; Zhu, Shuoji; Yin, He; Zhao, Mingyi; Guo, Huiming; Zhu, Ping

doi:10.1016/j.biopha.2020.110813

Cited by 15 publications

(6 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By injecting stem cells into the heart, damaged cardiomyocytes can be replaced or regenerated, thus, restoring cardiac tissue and function. 134 , 135 Besides, the paracrine effects of stem cells, such as the production of growth factors, cytokines, and anti-inflammatory substances stimulate tissue repair, decreased inflammation, promotion of angiogenesis, decreased fibrosis, and improved microenvironment within of injured heart tissue, can all thus enhance heart function. 136 , 137 Various drugs with promising effects on fibrosis and collagen deposition, attenuation activity in DCM models is summarized in Table 2 .…”

Section: Cardiac Hypertrophy and Cardiac Fibrosismentioning

confidence: 99%

A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy

Dhar,

Venkadakrishnan,

Roy

et al. 2023

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is characterized by structural and functional abnormalities in the myocardium affecting people with diabetes. Treatment of DCM focuses on glucose control, blood pressure management, lipid-lowering, and lifestyle changes. Due to limited therapeutic options, DCM remains a significant cause of morbidity and mortality in patients with diabetes, thus emphasizing the need to develop new therapeutic strategies. Ongoing research is aimed at understanding the underlying molecular mechanism(s) involved in the development and progression of DCM, including oxidative stress, inflammation, and metabolic dysregulation. The goal is to develope innovative pharmaceutical therapeutics, offering significant improvements in the clinical management of DCM. Some of these approaches include the effective targeting of impaired insulin signaling, cardiac stiffness, glucotoxicity, lipotoxicity, inflammation, oxidative stress, cardiac hypertrophy, and fibrosis. This review focuses on the latest developments in understanding the underlying causes of DCM and the therapeutic landscape of DCM treatment.

show abstract

Section: Cardiac Hypertrophy and Cardiac Fibrosismentioning

confidence: 99%

A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy

Dhar,

Venkadakrishnan,

Roy

et al. 2023

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

show abstract

“…Recent studies support the hypothesis that cardiomyocytes harbor no ability of self-renewal and replication, for they are terminally differentiated cells (Heallen et al 2019). Thus, it is believed that the damage and apoptosis of cardiomyocytes are mainly ascribed to cell necrosis (Nasser et al 2020). However, the latest research shows that cardiomyocyte apoptosis is also an important biological basis for the normal physiological function of the heart (Heallen et al 2019).…”

Section: Introductionmentioning

confidence: 95%

Vascular endothelial growth factor ameliorated palmitate-induced cardiomyocyte injury via JNK pathway

Wang

Zou

Liu

et al. 2021

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

Enhanced apoptosis of cardiomyocytes in suffering overloaded saturated fatty acids (SFAs) can result in myocardial infarction and cardiac dysfunction. The function of vascular endothelial growth factor (VEGF) in cardiomyocyte protection was not clearly described. To investigate the preservative effects of VEGF sensitization on ceramide-mediated programmed cell death of cardiomyocytes, palmitate-induced injury in H9c2 cells was established as an in vitro model. Results revealed that 0.5 mM palmitate application effectively led to debased viability and activated apoptotic factors. A significant time-dependent relation between PAL and cardiomyocyte injury was observed. The apoptosis rate was increased greatly after 16 h of treatment with 0.5 mM PAL. In addition, cell viability was restored by VEGF overexpression during treatment with 0.5 mM PAL. Reduced apoptosis rate and expression of caspase 3, Bax, and NF-κB p65 were observed in this process, while boosted Bcl-2, p-JNK/JNK expression and activity of caspase 3 were checked. However, p-ERK/ERK levels did not exhibit a significant change. These findings indicated the protective effects of VEGF in confronting the ceramide-induced cardiomyocyte apoptosis, and would devote therapeutic targets for cardiovascular safeguard in dealing with fatty acid stress.

show abstract

“…Stem cell-based therapy is a promising technique for doxorubicin-induced toxicity. Although it remains in preclinical studies, many researchers have examined the role of regenerative medicine as an alternative therapy to heart transplantation [4] [5].…”

Section: Introductionmentioning

confidence: 99%

Possible Ameliorative Effects of Different Treatment Regimens Using Bone Marrow-mesenchymal Stem Cells of Doxorubicin-induced Toxicity in Female Wistar Rats

Khaled,

Kamal,

Bakry

et al. 2023

Egypt. J. Biophys. Biomed. Engng.

View full text Add to dashboard Cite

A LTHOUGH cancer treatment is expensive with its new strategies such as immunotherapy, targeted therapy, gene therapy, and other new cancer medicines, the classic cytotoxic agents such as doxorubicin (DOX) remain the only affordable choice to the vast majority of patients despite its dose-dependent cardiotoxic effects. The current study aims to ameliorate the toxicity of DOX on female Wistar rats by using different treatment regimens with Bone marrow-derived mesenchymal stem cells (BM-MSCs). Female Wistar rats were divided into seven Groups, two non-treated groups; a control group, and a DOX non-treated, the other groups were treated with a single dose of BM-MSCs after 2, 24, 48, and 72 h of DOX injection, and one group was treated with equally fractionated BM-MSCs doses at 2 nd , 24 th , 48 th and 72 nd h after DOX treatment. Results revealed that early treatment with BM-MSCs increased liver protection which was confirmed by biochemical markers analysis as well as improved renal functions by restoring levels of urea and creatinine to normal levels and ameliorating pathological damage, cardiomyocyte apoptosis, and fibrosis in rat myocardial tissues. These results promote the use of BM-MSCs, which would be a preferable choice for patients receiving DOX. The fractionated group takes priority of the effective results in treating the toxicities of DOX over the rest of the treated groups. 2 and 24-hour treated groups come in 2nd place. Finally, 48 and 72-hour treated groups occupy the last place in effectiveness.

show abstract

Current situation and future of stem cells in cardiovascular medicine

Cited by 15 publications

References 95 publications

A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy

A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy

Vascular endothelial growth factor ameliorated palmitate-induced cardiomyocyte injury via JNK pathway

Possible Ameliorative Effects of Different Treatment Regimens Using Bone Marrow-mesenchymal Stem Cells of Doxorubicin-induced Toxicity in Female Wistar Rats

Contact Info

Product

Resources

About